Federal contract award
W81K0022P0269
HSV 1&2 DIRECT KITS & HSV 1 & 2 POSITIVE CONTROL PACK KITS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | W40M MRC0 WEST |
| NAICS | 325413 — In-Vitro Diagnostic Substance Manufacturing |
| PSC | 6550 — In Vitro Diagnostic Substances, Reagents, Test Kits and Sets |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $109.6K |
| Current contract value | $139.7K |
| Potential contract value / ceiling | $139.7K |
| Start date | Oct 1, 2022 |
| Current end date | Sep 30, 2027 |
| Potential end date | Sep 30, 2027 |
| Latest award activity | Apr 7, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 10 of 10 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Apr 7, 2026 | P00009 | $0 | PURSUANT TO FEDERAL ACQUISITION REGULATION (FAR) 52.217-9, OPTION TO EXTEND THE TERM OF THE CONTRACT, W81K00-22-P-0269 WITH DIASORIN MOLECULAR, LLC. IS HEREBY EXTENDED FOR THE PERIOD 01 OCTOBER 2026 - 30 SEPTEMBER 2027 (OPTION PERIOD 4). |
| Jan 7, 2026 | P00008 | $27.9K | IN ACCORDANCE WITH FEDERAL ACQUISITION REGULATION (FAR) 52.232-18, AVAILABILITY OF FUNDS, FY26 FUNDS ARE AVAILABLE AND HEREBY OBLIGATED FOR DELIVERY ORDER W81K00-22-P-0269 FOR THE PERIOD OF 1 OCTOBER 2025 - 30 SEPTEMBER 2026. |
| Aug 26, 2025 | P00007 | $-2.2K | THE PURPOSE FOR THIS MODIFICATION IS TO DE-OBLIGATE EXCESS FY23 FUNDS, IN ORDER TO REFLECT ACTUAL AMOUNTS USED DURING PERFORMANCE OF THE CONTRACT IN FY23 (01 OCTOBER 2022 - 30 SEPTEMBER 2023). |
| Jun 13, 2025 | P00006 | $0 | PURSUANT TO FEDERAL ACQUISITION REGULATION (FAR) 52.217-9, OPTION TO EXTEND THE TERM OF THE CONTRACT, W81K00-22-P-0269 WITH DIASORIN MOLECULAR, LLC. IS HEREBY EXTENDED FOR THE PERIOD 01 OCTOBER 2025 - 30 SEPTEMBER 2026 (OPTION PERIOD 3). |
| Dec 17, 2024 | P00005 | $27.9K | HSV 1&2 DIRECT KIT - FY25 FUNDING MODIFICATION |
| Apr 16, 2024 | P00004 | $0 | HSV 1&2 DIRECT KIT - EXERCISE THE FY25 OPTION YEAR |
| Nov 17, 2023 | P00003 | $27.9K | HSV 1&2 DIRECT KIT - FUNDING MODIFICATION |
| May 9, 2023 | P00002 | $0 | OPTION YEAR 1: HSV 1&2 DIRECT KIT |
| Nov 4, 2022 | P00001 | $27.9K | HSV 1&2 DIRECT KIT - FY23 FUNDING MODIFICATION |
| Sep 28, 2022 | 0 | $0 | HSV 1&2 DIRECT KITS & HSV 1 & 2 POSITIVE CONTROL PACK KITS |
Estimated positioning window
Oct 25, 2026 – Mar 30, 2027
80/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 80/100. Available recorded signals: 75 points.
- Contract end 2027-09-30 (340 days from calculation)
- +35 points
- 80 historical awards in this buyer and category group
- +15 points
- 10 recorded award transactions
- +10 points
- Latest award action: 2026-04-07
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.